<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35356830</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-1937</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of pharmacy practice</Title><ISOAbbreviation>J Pharm Pract</ISOAbbreviation></Journal><ArticleTitle>In It for the Long Haul: Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2.</ArticleTitle><Pagination><StartPage>1048</StartPage><EndPage>1051</EndPage><MedlinePgn>1048-1051</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">08971900221088799</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/08971900221088799</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has caused immeasurable clinical, economic, and societal challenges for the world since early 2020. Intense focus has been placed on determining evidence-based acute management of patients infected with the SARS-CoV-2 virus, as well as accelerating vaccination efforts for those eligible to receive it. As patients recover from infection, many are left with long-term symptoms, known as "Long COVID" or "Post-Acute Sequelae of COVID19," that challenges the ability to fully recover, return to baseline health status, and regain quality of life. As the most accessible healthcare professional, pharmacists can assist with the management of long COVID as a member of the multidisciplinary team. Pharmacists' medication acumen is beneficial to the management of long COVID symptomatology as more research comes to the forefront of this deadly disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gosser</LastName><ForeName>Rena</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7362-9219</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Washington Medicine - Harborview Medical Center, Seattle, WA, USA.</Affiliation><Identifier Source="RINGGOLD">21618</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Care Options, Reston, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blaszczyk</LastName><ForeName>Amie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice, Texas Tech University School of Pharmacy, Dallas, TX, USA.</Affiliation><Identifier Source="RINGGOLD">15496</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jen</LastName><ForeName>Christi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Mayo Clinic Arizona, Phoenix, AZ, USA.</Affiliation><Identifier Source="RINGGOLD">23387</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatt</LastName><ForeName>Snehal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA.</Affiliation><Identifier Source="RINGGOLD">1825</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pharm Pract</MedlineTA><NlmUniqueID>8900945</NlmUniqueID><ISSNLinking>0897-1900</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010595" MajorTopicYN="N">Pharmacists</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">long-haul COVID</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">syndrome coronavirus</Keyword></KeywordList><CoiStatement><b>Declaration of Conflicting Interests:</b> The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>31</Day><Hour>8</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35356830</ArticleId><ArticleId IdType="pmc">PMC8971963</ArticleId><ArticleId IdType="doi">10.1177/08971900221088799</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Perrin R, Riste L, Hann M, Walther A, Mukherjee A, Heald A. Into the looking glass: Post-viral syndrome post COVID-19. Med Hypotheses. 2020;144:110055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320866</ArticleId><ArticleId IdType="pubmed">32758891</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Palacios-Ce&#xf1;a D, G&#xf3;mez-Mayordomo V, et al.Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): An integrative classification. Int J Environ Res Publ Health. 2021;18(5):2621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7967389</ArticleId><ArticleId IdType="pubmed">33807869</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, et al.Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR. Morb Mortal Wkly Rep. 2020;69(30):993-998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Sude CH, Murra B, Varsavsky T, et al.Attributes and predictors of long COVID. Nat Med. 2021;27:626-631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al.Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their impactmedRxiv (Online Repository). 2020.12.24.20248802.</Citation></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al.Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly JP, Wang XQ, Iwashyna TJ, Prescott HC. Readmission and death after initial hospital discharge among patients with COVID-19 in a large multihospital system. JAMA. 2021;325(3):304-306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737131</ArticleId><ArticleId IdType="pubmed">33315057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavery AM, Preston LE, Ko JY, et al.Characteristics of hospitalized COVID-19 patients discharged and experiencing same-hospital readmission - United States, march-august 2020. MMWR. Morb Mortal Wkly Rep. 2020;69(45):1695-1699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7660660</ArticleId><ArticleId IdType="pubmed">33180754</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustbader D, Mudra M, Romano C, et al.The impact of a home-based palliative care program in an accountable care organization. J Palliat Med. 2017;20(1):23-28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5178024</ArticleId><ArticleId IdType="pubmed">27574868</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemelli Against COVID-19 Post-Acute Study Group . Post-COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clin Exp Res. 2020;32(8):1613-1620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7287410</ArticleId><ArticleId IdType="pubmed">32529595</ArticleId></ArticleIdList></Reference><Reference><Citation>Becnel D, McKendall M. The Effects of &#x201c;Long COVID&#x201d; and How Pharmacists Can Help. Drug Topics; 2021. accessed 2021 May 4https://www.drugtopics.com/view/the-effects-of-long-covid-and-how-pharmacists-can-help.</Citation></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequalae of COVID-19. Nature. 2021. Online ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward S, O&#x2019;Reilly R, Crawford P. Evaluating clinical pharmacist involvement in a COVID-19 intensive care recovery clinic. Pharmaceut J. 2021. online.</Citation></Reference><Reference><Citation>Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integrated Pharm Res Pract. 2017;6:37-46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5774321</ArticleId><ArticleId IdType="pubmed">29354549</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C. UIC Drug Information Group. What Should I, as a Pharmacist, Know about Long COVID?; 2021. accessed 2021 May 4https://dig.pharmacy.uic.edu/faqs/2021-2/march-2021-faqs/what-should-i-as-a-pharmacist-know-about-long-covid/.</Citation></Reference><Reference><Citation>Mullard A. Long COVID's long R&amp;D agenda. Nat Rev Drug Discov. 2021;20(5):329-331.</Citation><ArticleIdList><ArticleId IdType="pubmed">33879882</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>